Jickky Palmae Sarathy, Ph.D. Email & Phone Number

Singapore

Singapore

Nutley, New Jersey, United States

-Investigation of novel multi-drug regimens for treatment of non-tuberculous mycobacteria (NTM) infections via assessment of combination activity of current and repurposed drugs, as part of Professor Thomas Dick's research group.-Drive drug discovery projects to uncover potential drug candidates for antibiotic treatment of non-tuberculous mycobacteria (NTM) infections. This involves in vitro compound/drug screening and profiling, mechanism of action studies and in vivo efficacy determination.-Establish a platform for identifying compounds which induce targeted protein degradation in mycobacteria, a potentially novel approach for the development of next generation anti-tuberculosis drugs. -Assist with the overall running of the laboratory by managing the purchasing and keeping stock of the laboratory’s consumables

Nutley, New Jersey, United States

1) Gordon Research Conference (March 2024)-Gave a talk on my work on the development of a framework to rationally combine drugs to treat Mycobacterium abscessus lung disease at the Gordon Research Conference (New Antibacterial Discovery and Development - Innovative Approaches in Antibacterial Research and Development to Fight the Antibiotic Resistance Crisis) Link: https://www.grc.org/new-antibacterial-discovery-and-development-conference/2024/2) Colorado Mycobacteria Conference 2022: Focus on nontuberculous mycobacteria (June 2022)-Gave a talk at the “Colorado Mycobacteria Conference 2022: Focus on nontuberculous mycobacteria” (hosted by Colorado State University, Department of Microbiology, Immunology, & Pathology) on my project on OPC-167832, an anti-tuberculosis clinical drug candidate, as a potential repurposing candidate for Mycobacterium abscessus pulmonary disease treatment. 3) "The Advances in Antibacterial Discovery" virtual symposium (December 2021)-Gave a talk on my work on developing targeted protein degradation as a novel approach for uncovering new anti-tuberculosis drugs at "The Advances in Antibacterial Discovery" virtual symposium (hosted by St. Jude Children's Research Hospital, Department of Chemical Biology and Therapeutics)Link: https://www.stjude.org/education-training/advanced-training/seminars-symposia/advances-in-antibacterial-discovery.html4) Gordon Research Seminar (July 2019)-Gave a talk on my work on TBAJ-876, the promising new anti-tuberculosis clinical drug candidate, at the Gordon Research Seminar (Molecular and Cellular Insights in Tuberculosis: Identifying Novel Drugs and Therapeutic Targets)Link: https://www.grc.org/tuberculosis-drug-discovery-and-development-grs-conference/2019/

Singapore, Singapore

Part of a team of scientists that studied the mechanism of action of pyrazinamide, a standard-of-care drug used in the treatment of tuberculosis. My role in the project involved engineering an array of novel genetic constructs that were crucial in studying the drug's activity.

Doctor Of Philosophy - Phd, Medicine

-Part of a multi-disciplinary collaborative network (TB Alliance, Nanyang Technological University and National University of Singapore).

Bachelor'S Degree With Honours, Life Sciences (Specialization In Biomedical Science)